FDA Issues Warning Letters for Violations of MedTech Marketing and Good Manufacturing Practices Regulations

The U.S. Food and Drug Administration (FDA) has reportedly sent warning letters to several medical device manufacturers for violations of its device marketing and good manufacturing practices requirements.

According to a news item posted to the website of the Regulatory Affairs Professional Society (RAPS), the FDA recently sent warning letters to three different medical device companies. In at least one case, a company was cited for promoting the use of its devices to treat medical issues that are outside the scope of the device’s authorization.

In other cases, the companies were cited for their failure to implement current good manufacturing practices (CGMP) in connection with some of their products.

- Partner Content -

Critical Role of ESS in Data Center Safety and Resilience

Discover how energy storage systems (ESS) ensure data center resilience, mitigate risks like thermal runaway, and comply with critical standards. Learn about evaluation processes, benefits for stakeholders, and future trends in energy storage safety and reliability.

The companies reportedly cited by the FDA include Mectronic Medicale, a manufacturer of devices used to heat tissue to alleviate pain and muscle spasms, Visgeneer, which develops blood glucose monitoring systems, and Oasis Medical, a California-based drug company.

The RAPS article regarding the FDA’s warnings regarding non-compliance by device manufacturers is available at https://www.raps.org/news-and-articles/news-articles/2025/8/fda-issues-warning-letters-for-cgmp-violations,-ma.

Related Articles

Digital Sponsors

Become a Sponsor

Discover new products, review technical whitepapers, read the latest compliance news, and check out trending engineering news.

Get our email updates

What's New

- From Our Sponsors -